We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Renal Cell Carcinoma
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
George Yaghmour
Dec 15, 2015
Immunotherapy is good choice. However, considering the Good PS and CCRCC pathology would also consider Cabozantinib per Toni choueiri et al NEJM article.
George Yaghmour
Jan 04, 2016
Given the good PS and the extent of disease. Considering SBRT and debunking recurrent disease then consider further treatment. Also the updated results from expanded cohorts in CheckMate 016 confirmed initial safety findings and promising anti tumor activity for nivolumab + ipilimumab in patients with metastatic renal cell carcinoma. Overall survival for the combination in metastatic renal cell carcinoma is encouraging.
Angel Rodriguez
May 05, 2016
Another option is retreatment with the best tki used previously
Apr 25, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Andrew
Fintel
DO
George Yaghmour
Dec 15, 2015
George Yaghmour
Jan 04, 2016
Angel Rodriguez
May 05, 2016
Apr 25, 2024
Pending Moderator approval.